FDA
-
-
-
-
-
-
-
Ascendis launches YUVIWEL for achondroplasia in US market
-
-
-
-
-
-
-
Pharma Leaders Discuss Managing Revenue Management System Updates at Model N Rainmaker Panel Hosted by RevSavvy
-
-
-
-
-
-
-
Acromegaly Market Poised for Significant Expansion During the Forecast Period (2026-2036) as New Treatment Options Emerge | DelveInsight
-
-
-
-
-
-
-
Ascendis Pharma's (ASND) PDUFA Extension a Minor Issue - Cantor Fitzgerald
-
-
-
-
-
-
-
Ascendis Pharma Reports Third Quarter 2025 Financial Results
-
-
-
-
-
-
-
Dr. Jethro Ekuta Joins BP Logix Life Sciences Strategic Advisory Board
-
-
-
-
-
-
-
Ascendis Pharma (ASND) Submits U.S. NDA for TransCon CNP for the Treatment of Children with Achondroplasia
-
322,964 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

